In the future, the necessity of waiting for chest X-ray or lab test results to diagnose pneumonia and other lung ailments might vanish. Researchers have engineered a portable sensor prototype capable of identifying such conditions by analyzing human breath odor. The study’s findings have been presented in the journal Nano Letters.
Its operational foundation lies in analyzing nanoparticles that a patient inhales initially. Upon exhalation, these nanoparticles carry attached biomarkers, which can reveal signs of illness deep within the body.
The prototype was brought to life by a team from the Massachusetts Institute of Technology and is designated as PlasmoSniff.
This detection scheme has not yet undergone human trials, only animal testing on mice, suggesting that further development is required before its integration into routine medical practice. Nevertheless, the research collective remains optimistic about the potential success of their concept.
Based on the outcomes of forthcoming evaluations, they anticipate the sensor could evolve into a rapid and convenient tool for deployment in clinical settings or even residences, bypassing the need for laboratory electronics typically confined to hospital environments.
“In everyday application, we envision a scenario where a patient inhales the nanoparticles and subsequently exhales a synthetic biomarker reflecting their lung status after about ten minutes,” explains mechanical engineer Aditya Garg. “Our novel PlasmoSniff technology will enable the detection of these biomarkers in exhaled air within minutes, right at the point of care.”
The nanoparticles targeted by the sensor have been under development for several years. The biomarkers, or chemical tags affixed to them, detach upon interaction with specific proteases (tiny protein fragments) that are characteristic of particular diseases.
This dissociation yields a discernible signal for the researchers—however, these biomarkers are expelled in extremely small quantities. To detect these faint traces, the new system leverages an approach termed plasmonics (the study and manipulation of light), which inspires the name PlasmoSniff.
Specifically, the sensor utilizes a technique known as Raman spectroscopy, where light is employed to gauge molecular vibrations. These vibrations act as telltales for atomic movements within chemical bonds and can thus be utilized for molecular identification.
The sensor apparatus itself incorporates gold nanoparticles suspended above a thin gold film—gold being the optimal metal for plasmonic applications. Microscopic, water-filled gaps within the sensor capture the target biomarkers, amplifying their vibrations sufficiently for detection.
Human breath contains a vast array of Volatile Organic Compounds (VOCs), which offer clues spanning from the condition of the gut microbiome to the efficiency of the body’s metabolic processes. Yet, this newly devised sensor captures only a minuscule fraction of the chemicals expelled.
“This is analogous to searching for a needle in a haystack,” notes mechanical engineer Loza Tadesse. “Our approach manages to detect that singular ‘needle,’ which would otherwise be obscured within the background noise.”
Currently, the researchers remain in the prototype phase: they conducted testing on mice instead of humans and focused on monitoring only one specific biomarker.
Performing breath analyses on people will present a greater challenge, and the team also needs to engineer a mask-like attachment that can facilitate patient breath sampling over a period of approximately five minutes.
This apparatus will be paired with an inhaler, similar to those used for asthma, to introduce the nanoparticles. In healthy individuals, these nanoparticles will simply be expelled from the body without being broken down due to illness.
Should development and scaling prove successful in the upcoming years, this could represent a significant new modality for disease monitoring and diagnosis—a method that, according to the researchers, is adaptable to a wide array of applications beyond respiratory conditions like pneumonia.
It is conceivable that PlasmoSniff could find utility outside the healthcare sector as well, in any situation requiring the identification of minute traces of chemical substances in the air using a portable detector.
“This extends beyond just these specific biomarkers or even diagnostic uses,” comments Tadesse. “It is also capable of detecting industrial chemicals or atmospheric pollutants. If a molecule is capable of forming hydrogen bonds with water, we can utilize its vibrational spectrum for its detection. This is quite a versatile platform.”
About the Author
